Delivery Order SPE2DB25D3017-SPE2DB26FVGYM
- Not listed
- The Defense Logistics Agency awarded a $6,048.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections on October 31, 2025, with completion scheduled for November 3, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,113.91 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pen injectors. The award, issued on November 7, 2025, with a completion date of November 10, 2025, represents a firm fixed-price contract with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order...
- The Defense Logistics Agency awarded a $26,926.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Mounjaro 5 mg/0.5 ml pen injectors. The contract, which is not set-aside, represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be completed by October 28, 2025, with fulfillment occurring at...
- The Defense Logistics Agency awarded a $2,176.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pen injections on October 31, 2025, with completion scheduled for November 3, 2025. This contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside designation, and...
- The Defense Logistics Agency awarded a delivery order valued at $4,554.74 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pen injections (0.5 ml units) on August 18, 2025, with an ultimate completion date of August 19, 2025. The contract operates under firm fixed pricing with no set-aside designation, indicating competitive award through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,262.48 for Mounjaro 5 mg/0.5 mL pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $5,450.56 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections on November 14, 2025, with completion expected by November 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,088.36 for Mounjaro 15 mg/0.5 mL pen injections on June 16, 2025, with an ultimate completion date of June 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at approximately $1...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pen injectors on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a firm fixed-price, non-set-aside contract for delivery to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $11,766.11 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pen injectors on September 11, 2025, with completion scheduled for September 12, 2025. This is a firm fixed-price, non-set-aside contract with performance occurring at the vendor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB26FVGYMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,081.35 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 ml pen injections on November 12, 2025, with completion expected by November 13, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award selection. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's medical supply chain. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply diverse pharmaceutical products and medical supplies supporting military healthcare programs worldwide. Mounjaro, a diabetes medication, falls within the company's extensive portfolio of therapeutic products including specialty medications, vaccines, and medical supplies distributed to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 11/12/25 |